Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 3 boards, counting each seat separately. Longest: Alnylam Pharmaceuticals Inc., 3 years.
Alnylam Pharmaceuticals Inc.
Director
Fractyl Health Inc.
Director
Elevance Health Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 20, 2026 | Alnylam Pharmaceuticals Inc. | Grant or award | +838 | — | — |
| May 13, 2026 | Elevance Health Inc. | Grant or award | +563 | — | — |
| May 13, 2026 | Alnylam Pharmaceuticals Inc. | Option exercise | +11,250 | $70.20 | $789,750 |
| Mar 12, 2026 | Elevance Health Inc. | Open-market sale | −26 | $287.50 | $7,475 |
| Feb 2, 2026 | Elevance Health Inc. | Grant or award | +218 | — | — |
| May 8, 2025 | Alnylam Pharmaceuticals Inc. | Grant or award | +775 | — | — |
| Mar 13, 2025 | Fractyl Health Inc. | Open-market purchase | +8,550 | $1.17 | $10,004 |
| Mar 13, 2025 | Alnylam Pharmaceuticals Inc. | Option exercise | +2,750 | $131.21 | $360,828 |
| Jun 25, 2024 | Alnylam Pharmaceuticals Inc. | Option exercise | +8,500 | $131.21 | $1,115,285 |
| Jun 25, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −8,500 | $240.00 | $2,040,000 |
| May 29, 2024 | Alnylam Pharmaceuticals Inc. | Option exercise | +30,000 | $66.83 | $2,004,900 |
| May 29, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −10,121 | $148.21 | $1,500,033 |
| May 29, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −11,516 | $148.93 | $1,715,078 |
| May 29, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −63 | $149.76 | $9,435 |
| Feb 23, 2023 | Alnylam Pharmaceuticals Inc. | Option exercise | +136 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.